Clinical Trial Update: A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension [Phase 3]

View source ↗

Summary

A Phase III study evaluating the efficacy and safety of DWC202405, DWC202313, and DWC202314 in adults with essential hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• DWC202313
• DWC202314
• DWC202405

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED